Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY22 results · Apr–Jun 2021
Torrent Pharmaceuticals reported revenue from operations of ₹2,134.00 crore (up 3.8% from Q1 FY21) and net profit of ₹330.00 crore (up 2.8% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,134.00 | 2,056.00 | +3.8% | 1,937.00 | +10.2% |
| Other income | 40.00 | 4.00 | +900.0% | 39.00 | +2.6% |
| Total income | 2,174.00 | 2,060.00 | +5.5% | 1,976.00 | +10.0% |
| Profit before tax | 484.00 | 402.00 | +20.4% | 383.00 | +26.4% |
| Net profit for the period | 330.00 | 321.00 | +2.8% | 324.00 | +1.9% |
| EPS, basic (₹) | 19.53 | 18.98 | +2.9% | 19.16 | +1.9% |
| Net margin (%) | 15.5 | 15.6 | 16.7 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,695.00 | 1,727.00 | −1.9% | 1,468.00 | +15.5% |
| Other income | 50.00 | 7.00 | +614.3% | 91.00 | −45.1% |
| Total income | 1,745.00 | 1,734.00 | +0.6% | 1,559.00 | +11.9% |
| Profit before tax | 412.00 | 370.00 | +11.4% | 301.00 | +36.9% |
| Net profit for the period | 274.00 | 298.00 | −8.1% | 279.00 | −1.8% |
| EPS, basic (₹) | 16.21 | 17.63 | −8.1% | 16.48 | −1.6% |
| Net margin (%) | 16.2 | 17.3 | 19.0 |
Consolidated
- Filed with BSE
- 27 Jul 2021, 19:16 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2021, 19:16 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Audited
- Source
- XBRL filing on BSE